H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Last trade$48.21
Day change-$0.79 (-1.61%)
Day range$48.14 – $49.27
Volume195,289
Market cap$2.64B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.64B
Price / earnings
13.34×
Price / book
1.22×
Price / sales
0.74×
EV / sales
1.29×
EV / EBITDA
8.06×
Profitability
Earnings per share
$3.67
Return on assets
3.64%
Return on equity
9.12%
Dividend yield
1.97%
Liquidity and leverage
Debt / equity
0.95×
Current ratio
1.82×
Quick ratio
1.1×
Cash ratio
0.12×
Cash flow
Price / cash flow
9.12×
Price / free cash flow
26.37×
Free cash flow
$100.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FUL, quarterly periods
Line item
Q3 FY2026 Aug 29, 2026
Q2 FY2026 May 30, 2026
Q1 FY2026 Feb 28, 2026
Q4 FY2025 Nov 29, 2025
Q3 FY2025 Aug 30, 2025
Q2 FY2025 May 31, 2025
Q1 FY2025 Mar 1, 2025
Q4 FY2024 Nov 30, 2024
Revenue
$938.18M
$950.27M
$770.84M
$894.79M
$892.04M
$898.1M
$788.66M
$923.28M
Cost of revenue
$626.49M
$630.62M
$534.8M
$612.71M
$606.93M
$611.71M
$561.59M
$658.42M
Gross profit
$311.69M
$319.65M
$236.05M
$282.08M
$285.11M
$286.38M
$227.08M
$264.86M
Selling, general and administrative
$198.48M
$202.37M
$184.45M
$183.64M
$174.97M
$186.34M
$180.63M
$188.45M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$198.48M
$196.74M
$184.45M
$183.64M
$174.97M
$179.2M
$180.63M
$188.45M
Operating income
$113.21M
$122.92M
$51.6M
$98.44M
$110.14M
$107.19M
$46.45M
$76.41M
Interest expense
-$40.92M
-$32.76M
-$32.87M
-$32.81M
-$33.63M
-$34.87M
-$32.04M
-$33.62M
Income before taxes
$103.84M
$93.39M
$27.55M
$40.6M
$83.76M
$74.57M
$18.71M
-$525K
Income taxes
$24.66M
$25.58M
$7.42M
$11.93M
$16.53M
$32.73M
$5.95M
$7.89M
Net income
$79.18M
$67.81M
$21.05M
$29.73M
$67.23M
$41.85M
$13.26M
-$7.25M
Net income attributable to common shareholders
$79.18M
$67.81M
$21.05M
$29.73M
$67.16M
$41.83M
$13.25M
-$7.36M
EBITDA
$159.25M
$168.97M
$97.96M
$143.92M
$155.7M
$151.87M
$89.04M
$122.4M
Basic earnings per share
$1.46
$1.25
$0.38
$0.55
$1.23
$0.77
$0.24
-$0.13
Diluted earnings per share
$1.44
$1.23
$0.38
$0.54
$1.22
$0.76
$0.24
-$0.13
Recent news
Company coverage with links to the original publishers.
RPM International reported Q1 FY2027 mixed results with adjusted EPS beating estimates but sales missing slightly. Strong demand in emerging markets and engineered solutions drove growth, offset by raw material inflation and weak education/healthcare construction. The company narrowed FY27 guidance to mid-single-digit growth and raised inflation expectations to 9-11% for Q2. Analysts have revised estimates downward, and the stock received a Zacks Rank #4 (Sell) rating despite its recent 10.9% gain.
H.B. Fuller reported Q3 adjusted earnings of $1.52 per share, up 21% year-over-year and beating consensus estimates by 4.8%. Revenue grew 5.2% to $938.2 million, driven by strong pricing execution that offset a 3% volume decline. Adjusted EBITDA margin expanded 80 basis points to a record 19.9%. However, post-earnings estimates have trended downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.
H.B. Fuller Company priced $850 million in 7.625% senior unsecured notes due 2034 to finance its planned acquisition of Advanced Medical Solutions Group plc, repay existing debt, and refinance maturing notes. The company must redeem $450 million of the new notes if the acquisition is not completed by June 25, 2027. H.B. Fuller's stock has underperformed its industry over the past year.
H.B. Fuller's stock declined slightly after reporting Q3 2026 earnings that beat adjusted earnings estimates but missed on net revenue. The chemical company reported $938 million in revenue (up 5% YoY) and $1.52 adjusted earnings per share, exceeding the $1.47 consensus estimate but falling short of the $948 million revenue projection. The company maintained full-year guidance and tightened adjusted net income guidance to $4.70-$4.85 per share.
H. B. Fuller reported Q3 2026 revenue of $938.18 million, up 5.2% year-over-year, beating consensus estimates by 0.43%. EPS of $1.52 exceeded expectations of $1.45 by 4.83%. However, the stock has underperformed the market, declining 10.4% over the past month compared to the S&P 500's 1.3% gain, and carries a Zacks Rank #4 (Sell) rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 15, 2026
$0.245
Oct 29, 2026
recurring
Jul 30, 2026
$0.245
Aug 13, 2026
recurring
Apr 30, 2026
$0.245
May 14, 2026
recurring
Feb 5, 2026
$0.235
Feb 19, 2026
recurring
Oct 16, 2025
$0.235
Oct 30, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.